|Day Low/High||37.51 / 38.36|
|52 Wk Low/High||31.58 / 42.82|
Teva gets final approval from the FDA to start selling four dosage strengths.
The Zocor surprise has Teva's stock reeling, but the full effect is still being debated.
Cramer likes the Utah company, and would like it even more at 32.
Cramer is calling London-based Diageo a company with great growth and a great dividend.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.